收藏切换
International experience and Chinese exploration of regulatory model of gene therapy drugs
收藏切换
PDF
Xiao-yan GUAN1, Han-yu CHANG2, Mei-qi WANG1, Guang-sheng LIANG3, Ni YUAN1
Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(7) : 523 - 528
Less
收藏切换
Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(7): 523-528
Policy and Management
International experience and Chinese exploration of regulatory model of gene therapy drugs
Full
Xiao-yan GUAN1, Han-yu CHANG2, Mei-qi WANG1, Guang-sheng LIANG3, Ni YUAN1
Affiliations
  • 1.School of Public Health, Dalian Medical University, Dalian LIAONING 116044, China
  • 2.Department of Medical Insurance, the First Hospital of Lanzhou University, Lanzhou GANSU 730013, China
  • 3.The International Peace Maternity and Child Health Hospital, SHANGHAI 200030, China
Published: 2024-07-25 doi: 10.14109/j.cnki.xyylc.2024.07.08
Outline
收藏切换

As a new therapeutic modality, gene therapy drugs (GTDs) play a therapeutic role and also have many risks, which brings challenges to the regulation of GTDs. The United States (US) and the European Union (EU) have established a relatively perfect system in terms of the regulatory body, regulatory basis and listing regulation, which is worthy of China’s reference. China’s regulation of GTDs still exists in the regulatory basis level is not detailed, the regulatory content is not mature and transparent, the main body of the regulatory implementation and the body of the responsibility is not clear enough and other issues. It is suggested that our country can learn from the advanced experience of the US and the EU, divide and control the risk of GTDs, set up an expert technical team, establish an advisory committee, and strengthen international communication and exchange, so as to improve the regulatory system of GTDs and enhance the safety of such drugs in China.

genetic therapy  /  regulation  /  rare disease  /  biological products  /  investigational new drug application
Xiao-yan GUAN, Han-yu CHANG, Mei-qi WANG, Guang-sheng LIANG, Ni YUAN. International experience and Chinese exploration of regulatory model of gene therapy drugs[J]. Chinese Journal of New Drugs and Clinical Remedies, 2024 , 43 (7) : 523 -528 . DOI: 10.14109/j.cnki.xyylc.2024.07.08
Year 2024 volume 43 Issue 7
PDF
111
52
Cite this Article
BibTeX
Article Info
doi: 10.14109/j.cnki.xyylc.2024.07.08
  • Receive Date:2022-11-30
  • Online Date:2026-03-13
  • Published:2024-07-25
Article Data
Affiliations
History
  • Received:2022-11-30
  • Accepted:2024-04-10
Funding
Affiliations
    1.School of Public Health, Dalian Medical University, Dalian LIAONING 116044, China
    2.Department of Medical Insurance, the First Hospital of Lanzhou University, Lanzhou GANSU 730013, China
    3.The International Peace Maternity and Child Health Hospital, SHANGHAI 200030, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/10.14109/j.cnki.xyylc.2024.07.08
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT